Sector News

U.S. drug developer Raptor Pharmaceuticals explores sale

April 7, 2016
Life sciences

Raptor Pharmaceutical Corp, which develops drugs that treat orphan diseases, is in discussions with investment banks to hire a financial adviser to explore a potential sale, according to people familiar with the matter.

The move may not lead to a sale, the people said this week, asking not to be identified because the deliberations are confidential. Raptor did not respond to a request for comment.

By Carl O’Donnell

Source: Reuters

Related News

May 8, 2021

BD to spin off $1B diabetes care business into standalone public company

Life sciences

BD’s new company will have the freedom to expand its portfolio of tools and technologies for the chronic care of diabetes.

May 8, 2021

Galapagos cuts pipeline, targets €150M in savings after setbacks

Life sciences

The Belgian biotech is pulling out of metabolic diseases and osteoarthritis R&D to focus on its core therapeutic areas.

May 8, 2021

Catalent snares yet another Belgian CDMO to boost fast-growing cell and gene therapy campus

Life sciences

Catalent will use its new facility for commercial production of plasmid DNA, used to make a range of biologics, including viral vectors, mRNA and cell therapies.

Send this to a friend